SG11202108926YA - Use of ppar-delta agonists in the treatment of mitochondrial myopathy - Google Patents
Use of ppar-delta agonists in the treatment of mitochondrial myopathyInfo
- Publication number
- SG11202108926YA SG11202108926YA SG11202108926YA SG11202108926YA SG11202108926YA SG 11202108926Y A SG11202108926Y A SG 11202108926YA SG 11202108926Y A SG11202108926Y A SG 11202108926YA SG 11202108926Y A SG11202108926Y A SG 11202108926YA SG 11202108926Y A SG11202108926Y A SG 11202108926YA
- Authority
- SG
- Singapore
- Prior art keywords
- ppar
- treatment
- mitochondrial myopathy
- delta agonists
- agonists
- Prior art date
Links
- 201000002169 Mitochondrial myopathy Diseases 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962808137P | 2019-02-20 | 2019-02-20 | |
| PCT/US2020/019059 WO2020172421A1 (en) | 2019-02-20 | 2020-02-20 | Use of ppar-delta agonists in the treatment of mitochondrial myopathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202108926YA true SG11202108926YA (en) | 2021-09-29 |
Family
ID=72144463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202108926YA SG11202108926YA (en) | 2019-02-20 | 2020-02-20 | Use of ppar-delta agonists in the treatment of mitochondrial myopathy |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220117972A1 (en) |
| EP (1) | EP3927718A4 (en) |
| JP (1) | JP2022523645A (en) |
| KR (1) | KR20210134348A (en) |
| CN (1) | CN113710683A (en) |
| AU (1) | AU2020224129A1 (en) |
| BR (1) | BR112021016142A2 (en) |
| CA (1) | CA3127470A1 (en) |
| IL (1) | IL285500A (en) |
| MA (1) | MA55040A (en) |
| MX (1) | MX2021009938A (en) |
| SG (1) | SG11202108926YA (en) |
| TW (1) | TW202045152A (en) |
| WO (1) | WO2020172421A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202192025A1 (en) * | 2019-02-04 | 2021-12-15 | Ренео Фармасьютикалс, Инк. | APPLICATION OF A PPAR AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) |
| EP4085906A1 (en) * | 2021-05-06 | 2022-11-09 | Universite De Bordeaux | Composition comprising ppar-modulator and an urolithin derivative and uses thereof |
| AU2022286415A1 (en) * | 2021-06-02 | 2023-12-14 | Astellas Pharma Inc. | Methods of use of ppar agonist compounds and pharmaceutical compositions thereof |
| WO2023282306A1 (en) * | 2021-07-06 | 2023-01-12 | 国立大学法人東京大学 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DISEASE ASSOCIATED WITH REDUCTION OR DEFECT OF τM5U MODIFICATION |
| WO2023147309A1 (en) * | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
| CN114457114B (en) * | 2022-03-07 | 2023-07-14 | 中国人民解放军空军军医大学 | Construction method of animal model for conditional knockout of Fars2 gene |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776916B2 (en) * | 2004-04-28 | 2010-08-17 | The Uab Research Foundation | Nitrated lipids and methods of making and using thereof |
| JP5054028B2 (en) * | 2005-12-22 | 2012-10-24 | ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー | New compounds, their manufacture and use |
| EP3756661A1 (en) * | 2013-09-09 | 2020-12-30 | vTv Therapeutics LLC | Use of a ppar-delta agonist for treating muscle atrophy |
| WO2016057656A1 (en) * | 2014-10-08 | 2016-04-14 | Mitobridge, Inc. | Ppar-delta agonists for use for treating mitochondrial, vascular, muscular, and demyelinating diseases |
| EA202192025A1 (en) * | 2019-02-04 | 2021-12-15 | Ренео Фармасьютикалс, Инк. | APPLICATION OF A PPAR AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) |
-
2020
- 2020-02-20 CA CA3127470A patent/CA3127470A1/en active Pending
- 2020-02-20 EP EP20760229.3A patent/EP3927718A4/en not_active Withdrawn
- 2020-02-20 BR BR112021016142A patent/BR112021016142A2/en unknown
- 2020-02-20 KR KR1020217029674A patent/KR20210134348A/en unknown
- 2020-02-20 SG SG11202108926YA patent/SG11202108926YA/en unknown
- 2020-02-20 JP JP2021541542A patent/JP2022523645A/en active Pending
- 2020-02-20 TW TW109105552A patent/TW202045152A/en unknown
- 2020-02-20 AU AU2020224129A patent/AU2020224129A1/en not_active Abandoned
- 2020-02-20 US US17/428,090 patent/US20220117972A1/en active Pending
- 2020-02-20 MX MX2021009938A patent/MX2021009938A/en unknown
- 2020-02-20 CN CN202080030086.6A patent/CN113710683A/en active Pending
- 2020-02-20 WO PCT/US2020/019059 patent/WO2020172421A1/en unknown
- 2020-02-20 MA MA055040A patent/MA55040A/en unknown
-
2021
- 2021-08-10 IL IL285500A patent/IL285500A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020224129A1 (en) | 2021-10-07 |
| EP3927718A1 (en) | 2021-12-29 |
| CA3127470A1 (en) | 2020-08-27 |
| KR20210134348A (en) | 2021-11-09 |
| CN113710683A (en) | 2021-11-26 |
| WO2020172421A1 (en) | 2020-08-27 |
| IL285500A (en) | 2021-09-30 |
| US20220117972A1 (en) | 2022-04-21 |
| MX2021009938A (en) | 2021-10-13 |
| BR112021016142A2 (en) | 2022-01-04 |
| MA55040A (en) | 2021-12-29 |
| JP2022523645A (en) | 2022-04-26 |
| EP3927718A4 (en) | 2022-12-07 |
| TW202045152A (en) | 2020-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285500A (en) | Use of ppar-delta agonists in the treatment of mitochondrial myopathy | |
| IL273583A (en) | Use of cannabidiol in combination with 5-ht2b receptor agonists or amphetamins in the treatment of epilepsy | |
| IL269027A (en) | Treatment of lag-3 positive tumors | |
| IL261721A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| GB2568471B (en) | Use of cannabinoids in the treatment of epilepsy | |
| IL272300A (en) | Mavacamten for use in the treatment of hypertrophic cardiomyopathy | |
| MX2017005457A (en) | Gip agonist compounds and methods. | |
| GB201720020D0 (en) | Use of cannabinoids in the treatment of epilepsy | |
| EP3380086A4 (en) | Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer | |
| GB201703115D0 (en) | Use of cannabinoids in the treatment of leukaemia | |
| PT3615035T (en) | Use of 20-hydroxyecdysone and the derivatives thereof in the treatment of myopathies | |
| ZA201704726B (en) | Peptides and their use in the treatment of skin | |
| IL283547A (en) | Use of lentiviral vectors expressing factor ix | |
| IL270978B (en) | Grape skin for use in the treatment of dysbiosis | |
| IL277805A (en) | Use of gaboxadol in the treatment of substance use disorders | |
| IL268798A (en) | Use of zinc treated precipitated calcium carbonate in hygienic products | |
| IL288900A (en) | Treatment comprising fxr agonists | |
| HUE058652T2 (en) | Compounds and their use in the treatment of schistosomiasis | |
| IL275349A (en) | Use of hm4di in the treatment of seizure disorders | |
| IL275132A (en) | C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| IL274838A (en) | Use of mir101 or mir128 in the treatment of seizure disorders | |
| EP3648789C0 (en) | Mtmr2-s polypeptide for use in the treatment of myopathies | |
| SG11202105276TA (en) | Oligo-benzamide analogs and their use in cancer treatment | |
| MX370540B (en) | Combinations of cancer therapeutics. |